Abcam, ab265831, Human CPA4 knockout HeLa cell line

Size: 2 x 1000000Cells / vial / 1000000Cells / vial
CPA4 KO cell line available to order. KO validated by. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: Insertion of the selection cassette in exon 6. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: Insertion of the selection cassette in exon 6,
Disease:Adenocarcinoma

Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-CPA4, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Zygosity-Homozygous, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CPA4 also known as Carboxypeptidase A4 is a type of zinc metalloprotease enzyme. It weighs about 47 kDa. CPA4 is primarily found in tissues like the prostate ovaries and placenta. The protein plays a role in processing the C-terminal ends of various proteins which is essential for the maturation and stabilization of other peptides and proteins. Its substrate specificity is similar to other metallocarboxypeptidases but may exhibit unique functions due to its expression profiles.
Biological function summary
Carboxypeptidase A4 contributes to the breakdown of peptides by removing terminal amino acids. It can operate as a single enzyme or potentially associate with other factors though specific complex formations with CPA4 are not well-documented. This proteolytic activity can regulate peptide hormone activity and aid in the final stages of protein digestion. The activity of CPA4 is also influenced by its interaction with zinc ions which are necessary for its catalytic function.
Pathways
CPA4 takes part in metabolic and digestive enzyme pathways. It specifically relates to pancreatic digestive pathways where it interacts with other proteins such as Carboxypeptidase B and C. These enzymes together coordinate the processing of dietary proteins converting them into amino acids readily absorbable by the body. CPA4's precise role in these pathways helps maintain digestive efficiency and nutrient absorption.
CPA4 has associations with some types of cancer such as prostate cancer possibly related to its expression in prostate tissue. Researchers have also explored links between CPA4 activity and the development of certain genetic disorders. Associations between CPA4 and insulin-like growth factor-binding proteins suggest pathways through which CPA4 might influence cell growth and proliferation potentially connecting it to oncogenic processes.